For years the strategy was to not acknowledge the science and strength of clinical trials.
This delayed success and adoption of cell therapy. They actually achieved everything they set out to do.
Stem cell companies were forced to run long trials right to phase 3 .... taking over 12 years at at least
Now phase 3 trials are ready to read out and finish. Japan and China are ready to embrace the new obviously better treatments.
I invested in Stem cell companies at least 5 years to early. That did not make my investment wrong.
I underestimated the status quo and believed they would embrace the new paridigm...boy was I wrong
I believe the sector and science is being validated now!
Good luck fellow visionaries....Its been a long road
- Forums
- ASX - By Stock
- MSB
- IMO big pharma is really gambling by putting off partnering
IMO big pharma is really gambling by putting off partnering
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $18.34M | 14.84M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 104582 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 56681 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 66410 | 1.245 |
17 | 128320 | 1.240 |
13 | 174981 | 1.235 |
12 | 103365 | 1.230 |
7 | 78900 | 1.225 |
Price($) | Vol. | No. |
---|---|---|
1.250 | 45117 | 5 |
1.255 | 133765 | 22 |
1.260 | 252808 | 12 |
1.265 | 235257 | 16 |
1.270 | 306709 | 12 |
Last trade - 15.07pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online